Although fusion remained dependent on CD4 and chemokine receptor binding, the endosome inhibitors did not alter surface expression of CD4 and CXCR4. These results suggest that fusion in the presence of the endosome inhibitors likely occurs within nonacidified endosomes. However, the ability of these inhibitors to impair vesicle trafficking from early to late endosomes in some cells could also increase the recycling of these virioncontaining endosomes to the cell surface, where fusion occurs. In summary, our results reveal an unexpected, CD4-mediated reciprocal relationship between the pathways governing HIV virion fusion and endocytosis.
Human immunodeficiency virus type 1 (HIV-1) virions enter cells by fusion or endocytosis, with sharply different functional consequences. Fusion, which occurs at the plasma membrane and does not require pH-dependent changes in envelope conformation, promotes the insertion of HIV cores into the cytoplasm and often leads to productive infection (for a review, see references 3, 8, 11, and 13). The HIV-1 Nef protein accelerates viral pathogenesis and enhances viral infectivity, in part by increasing the cytoplasmic delivery of HIV cores through the fusion pathway (9, 17, 20, 25, 28, 32) . In contrast, the endocytic pathway culminates in virion inactivation in acidified endosomes or degradation in lysosomes and, in most cells, nonproductive infection (19, 22, 27, 29, 30, 33) .
In certain cell types, however, vesicular uptake of HIV virions may have important functional consequences. In dendritic cells, dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN)-mediated capture and endocytosis of HIV virions may play a key role in HIV dissemination. Recycling of vesicles containing these virions to the cell surface likely facilitates productive infection of T cells interacting with the dendritic cell (4, 18) . The spread of HIV seems to be enhanced by endocytosis, suggesting that either mild acidification of virions or trafficking of these virion-laden vesicles to the site of cellcell contact facilitates virion transmission. In macrophages, HIV virions are actively internalized into large vesicles by a receptor-independent process called macropinocytosis. Although the majority of virions internalized in this manner are degraded, a few engage CD4 and chemokine receptors on the internal surface of the macropinosome, leading to HIV core release into the cytoplasm and thereby contributing to productive infection (23) .
Endocytosis is an active pathway for virion uptake in epithelial cells. In HeLa-CD4 cells, 85 to 90% of the virions enter by endocytosis. This process, which does not require either CD4 or chemokine coreceptor engagement, promotes the passage of cargoes through a series of discrete vesicular compartments, including early and late endosomes, which differ in acidity (pH 6.2 versus 5.5, respectively) due to the action of a vacuolar proton ATPase. Within 1 to 2 min after internalization, endocytosed cargoes reach the early endosome, where a sorting reaction occurs (24) . Certain cargoes are recycled back to the plasma membrane, whereas others destined for degradation are transported to perinuclear late endosomes before entering lysosomes. Endosomal carrier vesicles have been proposed to mediate microtubule-dependent transfer of cargoes from early to late endosomes. In some cells, potent inhibitors of the vacuolar proton ATPase, such as bafilomycin A1, not only block acidification of the early endosome but also impair transport of cargoes to the late endosomes (2) .
Whether endocytosed HIV virions ever mediate productive infection of target cells has been a topic of considerable debate. Retroviruses generally infect cells by a receptor-dependent but pH-independent fusion reaction at the plasma membrane. However, a fraction of HIV virions entering the endocytic pathway might fuse to target cells within endosomes before inactivation. In support of this notion, NH 4 Cl, a lysomotropic weak base that impairs endosome and lysosome acid-ification, modestly enhanced HIV infectivity (1). More recently, potent inhibitors of endosome acidification, like bafilomycin A1 and concanamycin A, have been shown to produce a 2-to 15-fold enhancement of HIV-1 NL4-3 , HIV-1 SF2 , and HIV-1 LAI infectivity in epithelial Magi cells (a HeLa cell derivative) (16) . In another study, these agents had similar effects on infectivity with HIV-1 NL4-3 , but blockade of endosomal acidification with bafilomycin impaired rather than enhanced the infectivity of HIV-1 SF2 (14) .
However, several important questions remain unresolved. First, are there differences in the endocytic properties of biologically relevant cellular targets, (e.g., primary CD4 T lymphocytes versus epithelial HeLa CD4 cells)? Second, do endosome inhibitors similarly enhance HIV infectivity in CD4 T lymphocytes? Third, if HIV infectivity is enhanced by endosome inhibitors, does the fusion reaction require HIV Env engagement of CD4 and the appropriate chemokine coreceptor? Fourth, in view of the effects of bafilomycin on both endosome acidification and trafficking, does fusion occur within the endosome or at the plasma membrane?
In the present report, we investigate these key questions, revealing an intriguing compensatory relationship between HIV fusion and endocytosis governed by the common involvement of CD4 in both entry events.
cotransfected with proviral NL4-3⌬env (50 g), pCMV-VSV-G (10 g), pCMVBlaM-Vpr (20 g), and pAdvantage (10 g). Viruses were harvested from the supernatant 48 h later, and cellular debris was removed by low-speed centrifugation. Viral particles were subsequently concentrated via ultracentrifugation at 20,000 rpm in an SW41 rotor (Beckman) for 2 h at 4°C, resuspended in 1 ml of Dulbecco's modified Eagle's medium and aliquoted for storage at Ϫ80°C. pCMV-BlaM-Vpr (generously provided by Marielle Cavrois, Gladstone Institute of Virology and Immunology) has been previously described (7) , and the NL4-3⌬env clone was generated by end filling of an NheI digest of NL4-3 (kindly provided by C. de Noronha, Gladstone Institute of Virology and Immunology).
Flow cytometric analysis. Human SupT1 T cells (10 5 ) or PHA-activated lymphoblasts (2 ϫ 10 5 ) were resuspended in fresh medium in the presence or absence of AMD3100 (5 g/ml) or with purified mouse anti-human monoclonal anti-CD4 antibodies (20 g/ml; Pharmingen International) at 37°C for 30 min before exposure to virus. GFP-Vpr-labeled HIV-1 (150 to 300 ng of p24 Gag) was added for 3 h at 37°C or at 4°C. Cells were washed with phosphate-buffered saline (PBS) or treated with a trypsin-EDTA solution (1ϫ; Sigma) for 2 min at room temperature to remove surface-bound virions, followed by additional washing and fixation in 1% paraformaldehyde-PBS solution. For quantitation of CD4-positive PHA-activated lymphoblasts, cells were resuspended in PBS-1% FBS (100 l) and stained for 30 min at 4°C in the dark with a 1:50 dilution of phycoerythrin (PE)-or allophycocyanin (APC)-conjugated mouse monoclonal CD4 antibodies (Caltag Laboratories) or with immunoglobulin G (IgG) isotype control antibodies. After one additional wash, cells were resuspended in PBS.
SupT1 cells were either untreated or incubated with bafilomycin A1 (100 nM) or concanamycin A (0.6 nM) for 3 h at 37°C. Cells were washed with PBS-1% FBS and stained with PE-conjugated anti-CD4, anti-CXCR4 monoclonal antibody, or IgG2a isotype control (1:50 dilution; all from Pharmingen) for 30 min at 4°C in the dark. After one wash, cells were resuspended in PBS, and the fluorescence intensity was analyzed by flow cytometry (FACSCalibur; Becton Dickinson, San Jose, Calif.). For each condition, 2 ϫ 10 5 events were acquired, and cells in the live cell gate were analyzed with CellQuest software.
Virion-based fusion assay. The virion-based fusion assay was performed as described previously (7) . Briefly, 250,000 SupT1 cells were pretreated with DMSO (0.1%; diluent control), AMD3100 (250 nM), bafilomycin A1 (10 nM), concanamycin A (1 nM), or NH 4 Cl (10 mM) for 1 h at 37°C. BlaM-Vpr-labeled virions (25 to 100 ng of p24 Gag) were then added and incubated for a further 3 h at 37°C in the continued presence of drugs as indicated. Virions were then removed by washing the cells once with CO 2 -independent medium (Gibco-BRL, Rockville, Md.), and the cells were loaded with CCF2/AM dye by incubation for 1 h at room temperature in CO 2 -independent medium supplemented with CCF2/AM and pluronic acid as suggested in the manufacturer's instructions (Aurora Biosciences). The cells were then washed twice with CO 2 -independent medium, and the BlaM reaction was allowed to incubate overnight in CO 2 -independent medium supplemented with 10% FBS and 2.5 mM probenecid (Sigma Pharmaceuticals, St. Louis, Mo.). The cells were washed once with PBS and fixed in 1.25% paraformaldehyde for 2 h. The change in emission fluorescence of CCF2 after cleavage by BlaM-Vpr was then monitored by flow cytometry using a three-laser Vantage DIVA (Becton Dickinson) as previously described (7) . Data were collected with CellQuest and analyzed with FlowJo software (Treestar, San Carlos, Calif.).
Infectivity analysis. Human SupT1 T cells (2 ϫ 10 5 ) were pretreated at 37°C for 30 min with AMD3100, anti-CD4 antibodies, bafilomycin A1, concanamycin A, nocodazole, or NH 4 Cl at the indicated concentrations and infected with HIV-1 pNL4-3 or HIV/VSV-G pseudotypes (50 ng of p24 Gag) for 16 h. Excess free virus was removed by serial washing. HIV-1 replication was monitored by measuring p24 Gag levels in the culture supernatants during subsequent culture.
Single-cycle infectivity studies were performed with MAGI cells pretreated at 37°C for 30 min with either DMSO (diluent control), bafilomycin A1, concanamycin A, nocodazole, or NH 4 Cl followed by infection with HIV-1 (1 to 20 ng of p24 Gag) in 48-well plates for 16 h. Viral spread was prevented by addition of soluble CD4 (2 g/ml) after 16 h. The cells were fixed 48 h after infection and incubated with the ␤-galactosidase substrate, 5-bromo-4-chloro-3-indolyl-␤-Dgalactopyranoside. Blue-staining cells were enumerated by light microscopy.
RESULTS
HIV-1 entry and replication in the presence of anti-CD4 blocking antibodies or AMD3100. HIV-1 virions labeled with GFP-Vpr fusion proteins were used to monitor virion entry into target cells. These fluorescent virions were prepared as described in Materials and Methods. X4-or R5-tropic virions were added to the different cellular targets for 3 h at 37 or 4°C in the presence or absence of blocking anti-CD4 antibodies or the AMD3100 bicyclam inhibitor of CXCR4-dependent fusion (31) . Selected aliquots of these cells were treated with trypsin to remove noninternalized, surface-bound virions prior to analysis by flow cytometry ( Similar studies were performed with biologically relevant primary human T lymphocytes as cellular targets in the X4-tropic HIV binding and entry assays ( 
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of 300 ng of p24 Gag, approximately 8.5% of these cells bound, and 6.3% internalized, the fluorescent HIV virions ( Fig. 2A) .
Binding of virions at 4°C followed by trypsin treatment yielded Յ0.7% positive cells ( Fig. 2A) . Two-color immunofluorescence studies revealed that virion entry during the 3-h incubation was almost exclusively restricted to the CD4 subset of PHA-activated lymphoblasts. As observed with the SupT1 cells, total virion entry into these CD4 T lymphoblasts was not impaired by AMD3100 (Fig. 2B , compare panels 2 and 3).
Even after a 24-h exposure to these HIV virions (Fig. 2C) , the CD4-positive cells were the major cellular subset containing fluorescent virions (panel 2, 14% CD4-positive cells versus 2.3% CD4-negative cells). Further, entry of these virions into the CD4-positive PBMCs was not impaired by AMD3100 (Fig.  2C, panel 3 ). As expected, after a 24-h infection with VSV-Gpseudotyped HIV virions, which are internalized via endocytosis in a CD4-independent manner (1), both CD4-positive (16%) and CD4-negative (13%) cells contained fluorescently labeled virions (Fig. 2C, panel 4) . These results suggest that virion engagement of CD4 is required not only for fusion but also for endocytosis in PBMCs. The efficiencies of the AMD3100 fusion inhibitor and the blocking anti-CD4 antibodies were assessed in viral replication assays in which SupT1 cells served as targets for HIV-1 infection with X4 or R5 strains of NL4-3 viruses (Fig. 3) . Both AMD3100 and the anti-CD4 blocking antibodies markedly inhibited production of p24 Gag in the supernatants of the SupT1 cells cultures infected with X4 NL4-3 viruses. As expected, no productive viral infection occurred when R5 NL4-3 viruses were added, consistent with the absence of CCR5 receptors on the target cells. These findings confirmed that AMD3100 is biologically active in this culture system.
Through cell fractionation studies, it has been previously demonstrated by both our lab (30) and others (22) that approximately 50% of HIV-1 virions enter T cells by fusion and 50% enter by endocytosis. Thus, the finding in this study that AMD3100 effectively blocked viral replication (Fig. 3) but did not impair viral entry (Fig. 1A, panel 7 , compare with panel 3) suggests that a compensatory increase in endocytosis occurred FIG. 2 . Flow cytometric analysis of PHA-activated human lymphoblasts infected with GFP-Vpr-labeled HIV-1 virions. (A) PBMCs activated with PHA and cultured in interleukin-2 for 4 days were inoculated with GFP-Vpr-labeled X4-tropic HIV-1 (300 ng of p24 Gag) at 37 or 4°C as indicated. After 3 h, the cells were washed at room temperature with PBS (ϪT) or a trypsin-EDTA solution (ϩT) to remove surface-bound virions. Live cells were then analyzed by flow cytometry to detect GFP epifluorescence. Error bars indicate standard deviations of the mean derived from two independent experiments. (B and C) PHA-activated human lymphoblasts were pretreated for 30 min at 37°C with either medium (panels 2 and 4) or AMD3100 (panels 3 and 5). Cells were then incubated at 37°C for 3 or 24 h with GFP-Vprlabeled X4-tropic HIV-1 or HIV virions pseudotyped with the VSV-G envelope (200 ng of p24 Gag) at 37°C. Cells were subsequently stained with APC-conjugated CD4 antibodies (B) or PE-conjugated CD4 antibodies (C). Cells were analyzed for GFP epifluorescence and APC or PE immunofluorescence. The percentage of cells in each quadrant is indicated. Data shown are from a representative experiment performed three times with comparable results. Note preferential entry of HIV into CD4 cells and the absence of inhibitory effects of AMD3100 measured either at 3 or 24 h .   FIG. 3 . Neutralizing anti-CD4 antibodies and the X4-specific AMD3100 entry inhibitor efficiently block replication of X4-tropic HIV in SupT1 cells. HIV-1 NL4-3 X4 and R5 viruses (100 ng of p24 Gag) were incubated with SupT1 cells pretreated for 30 min at 37°C with AMD3100 or neutralizing anti-CD4 antibodies. After 3 h at 37°C, the cultures were extensively washed. After 2 days of culture, p24 Gag present in the cell medium was quantitated by ELISA. Data represent an average of three independent infections performed in duplicate. Error bars indicate standard deviations. AMD3100 did not impair overall entry of X4-tropic virions into SupT1 cells (Fig. 1A) but markedly impaired viral replication.
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in the presence of this bicyclam inhibitor. The fact that HIV-1 virion entry by endocytosis does not generally lead to productive infection is consistent with the lack of viral replication observed in the presence of AMD3100 despite unaltered virion uptake. In contrast, the inhibitory effect of anti-CD4 antibodies on total virion entry (Fig. 1A, panel 5 ) suggests that CD4 is required for HIV virion entry via both fusion and endocytosis. The involvement of the CD4 receptor in HIV-1 endocytosis in these T cells contrasts with the high levels of CD4-independent endocytosis of HIV-1 previously observed in epithelial HeLa cells (30) . Together, these results not only highlight important cell type differences in the receptor requirements for endocytosis of HIV but also reveal an intriguing interrelationship between entry by fusion and endocytosis in human T lymphocytes. HIV-1 replication and inhibitors of endosomal acidification and transport. Since inhibition of virion entry through the fusion pathway increased HIV-1 entry by endocytosis, we next investigated whether inhibition of the endocytic pathway would increase HIV entry by fusion. Two classes of endosome inhibitors, including lysosomotropic weak bases (NH 4 Cl) and inhibitors of the vacuolar proton ATPases (bafilomycin A1 and concanamycin A), were tested. Both impair the replication of viruses when fusion occurs within acidified endosomes and is associated with requisite pH-induced conformational changes in Env structure (1, 2, 22, 23) . Of note, bafilomycin A1 and concanamycin A not only block endosome acidification but also may arrest vesicular trafficking from early to late endosomes (2). The microtubule-disrupting agent nocodazole does not affect endosomal pH but inhibits the microtubule-dependent transport of endosomal carrier vesicles to late endosomes (2) .
These endosome inhibitors were first tested for effects on the replication of the WT strain as well as on the ⌬Nef strain of HIV-1 in SupT1 cultures. Nef is an auxiliary protein of HIV that is required for maximal delivery of HIV cores into the cytoplasm and for full HIV replication. Interestingly, the Nef phenotype of infectivity can be overcome by pseudotyping of HIV virions with the VSV-G protein, which targets these viruses for entry into endosomes where fusion occurs following acidification (1) . Accumulation of p24 Gag in the culture supernatant was measured 48 h after infection. Replication of the HIV-1 WT was increased 2.5-fold in the presence of bafilomycin A1 (100 nM) and concanamycin A (0.6 nM) and 1.5-fold in the presence of NH 4 Cl (10 mM) and nocodazole (Fig. 4A , solid bars). Even greater relative increases in viral replication were obtained when HIV-1 NL4-3 ⌬Nef viruses were tested with these endosome inhibitors (Fig. 4A, open bars) . Specifically, pretreatment with bafilomycin A1, concanamycin A, and NH 4 Cl produced three-, four-and twofold increases in HIV ⌬Nef viral replication, respectively (Fig. 4A) . Conversely, pretreatment of SupT1 cells with comparable concentrations of these endosome acidification inhibitors markedly inhibited replication of HIV/VSV-G-pseudotyped virions (Fig. 4B) .
We next compared the effects of these endosomal acidification and trafficking inhibitors on a single cycle of HIV-1 replication in MAGI cells (HeLa cells expressing CD4 and a Tat-activated HIV-LTR-␤-galactosidase reporter gene). The number of positive blue MAGI cells infected with NL4-3 WT increased 1.5-to 2-fold after 30 min of pretreatment with maximal concentrations of bafilomycin A1, concanamycin A, or NH 4 Cl that did not alter cell viability. These relatively modest increases are in agreement with a previous report (22) . We next tested the effects of the inhibitors on HIV-1 viruses displaying lower infectivity, including NL4-3 ⌬Nef and SF2 viruses. After pretreatment with bafilomycin A1 or concanamycin A, the replication of ⌬Nef HIV-1 increased to levels comparable to that of WT HIV-1 in untreated cells (Fig. 5A) , and the infectivity of SF2 increased roughly fivefold (Fig. 5B) . In the presence of these endosome inhibitors, the expression of . After incubation for 3 h at 37°C, the cells were washed. Two days later, p24 Gag in the culture medium was quantitated by ELISA. Data represent an average for three independent infections performed in duplicate. Error bars indicate standard deviations. The endosome inhibitors bafilomycin A1, concanamycin A, and NH 4 Cl enhanced the replication of both WT and ⌬Nef viruses but impaired replication of VSV-G pseudotypes of HIV where fusion is dependent on endosome acidification.
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SF2 ⌬Nef viruses increased 12-to 15-fold, which surpassed replication of SF2 WT in untreated cells (Fig. 5B) . Nocodazole did not significantly affect viral infectivity. These results demonstrate that inhibitors of endosome acidification enhance the replication of HIV both in T cells and in epithelial HeLa-CD4 cells. Even greater increases in the replication of viruses displaying intrinsically diminished infectivity (i.e., ⌬Nef mutants and SF2) are obtained in the presence of these inhibitors. HIV-1 fusion is enhanced in the presence of endosome inhibitors. SupT1 cells preincubated with endosome inhibitors were inoculated with GFP-Vpr-labeled virions for 3 h at 37°C and then trypsinized to remove virions bound at the cell surface. Flow cytometric assays showed that bafilomycin A1 and NH 4 Cl produced fivefold and twofold increases, respectively, in the number of GFP-positive cells (Fig. 6 ). Both the overall levels of virion binding (measured in the absence of trypsin) and virions entering cells (measured in the presence of trypsin) were increased.
To examine whether HIV-1 entry by fusion is increased in the presence of endosome inhibitors, we employed a virionbased fusion assay we recently described (7) that measures cytosolic delivery of BlaM from virions into target cells. BlaM, fused to the viral protein Vpr, is packaged into virions, and delivery of BlaM-Vpr to cells can be subsequently detected by a change in fluorescence emission of target cells loaded with the fluorescent dye CCF2. This assay has been demonstrated to discriminate between fusion and endocytosis of virions due to the lack of CCF2 availability within endosomes (7) .
SupT1 cells pretreated with various HIV-1 entry or endosome inhibitors were inoculated with BlaM-Vpr-labeled virions for 3 h at 37°C. Cells were subsequently loaded with CCF2, and the fluorescence emission of the cells was analyzed by flow cytometry. Under these conditions, on average, after 3 h of incubation with virus in the absence of any inhibitors, 90% of cells fused with VSV-G-pseudotyped virions while 5% of cells fused with WT NL4-3 (data not shown). However, upon pretreatment of SupT1 cells with endosome inhibitors, WT NL4-3 virus entry was increased up to fourfold while VSV-Gpseudotyped NL4-3⌬env virus entry was fully inhibited (Fig.  7A) . Entry specifically involved CXCR4, since AMD3100 treatment completely blocked WT NL4-3 virus entry while AMD3100 treatment slightly enhanced the already robust entry mediated by VSV-G-pseudotyped NL4-3⌬env. Thus, treatment of cells with endosome inhibitors led to an increase in virion fusion with SupT1 cells, suggesting that viruses present in neutralized endosomes are available for entry into the target cell through fusion mediated by the CXCR4 chemokine coreceptor. This increase in entry via fusion could thereby enhance productive infection of cells upon inhibition of endocytosis (Fig. 4) , suggesting that inhibition of endocytosis results in either increased fusion from within neutralized endosomes or recycling of vesicles to the cell surface and enhanced fusion at the plasma membrane.
To confirm that the enhancement of virion entry observed in the presence of the endosome inhibitors led to increased cytoplasmic delivery of viral cores, we performed subcellular fractionation studies. MAGI cells, which are more suitable than T cells for such fractionation studies, were pretreated with bafilomycin A1 or medium and incubated with NL4-3 WT or ⌬Nef virus for 1 h at 37°C. Cytosolic fractions were prepared and analyzed for p24 Gag content, which is expressed as a percentage of the whole-cell p24 Gag detected (Fig. 7B ). After infection with NL4-3 WT virus, the cytosolic p24 Gag content was approximately 11%. Preincubation with bafilomycin A1 increased fusion-mediated virus entry 1.5-fold (lanes 1 and 2) . Infection with ⌬Nef HIV-1 yielded lower levels of cytosolic p24 Gag (6%, lane 3). Bafilomycin A1 pretreatment of these ⌬Nef HIV-1-infected cells increased the cytosolic levels of p24 Gag 2.2-fold (lane 4) to approximately the levels in untreated cells incubated with WT virus. These entry findings coupled with the replication results indicate that treatment of target cells with endosome inhibitors enhances virion entry via the productive fusion pathway. The additional finding that these inhibitors increased the surface binding of virions raises the possibility that the endocytic process is altered in a manner that leads to increased surface virions. As such, a proportion of the increased cytosolic entry events could occur as a result of fusion at the cell surface.
Cell surface expression of CD4 and CXCR4 with endosome inhibitors. One possible mechanism to explain the increased surface virion binding in the presence of the endosome inhibitors would be an induced increase in surface CD4 or CXCR4 receptor expression. However, flow cytometric analyses of SupT1 cells treated with bafilomycin A1 or concanamycin revealed no effects on the levels of surface CD4 or CXCR4 receptors (Fig. 8) . These findings in T cells are in agreement with a recent analysis of CD4 and CXCR4 receptor expression in MAGI cells (16) and would suggest that fusion in the presence of the endosome inhibitors likely occurs within nonacidified endosomes.
DISCUSSION
Our studies have focused on HIV virion entry into the cell by two pathways, fusion and endocytosis. In general, virions entering by fusion support continuation of the HIV replicative life cycle, while endocytosis of virions leads to their inactivation in the acidified environment of endosomes and degrada- tion in lysosomes. However, our studies have revealed an unexpected compensatory interplay between these two entry pathways, explained by the common involvement of CD4. CD4 receptors are required not only for HIV fusion but also for endocytosis in T cells and PHA-activated lymphoblasts. CD4 binding plays a key initial role in the fusion of HIV virions at the plasma membrane by promoting conformational changes in gp120 that facilitate subsequent engagement of specific chemokine coreceptors (CCR5 or CXCR4). Conversely, based on studies in epithelial HeLa cells, endocytosis of HIV virions requires neither CD4 nor chemokine coreceptor binding (22, 30) . However, in human SupT1 T cells or PHA-activated lymphoblasts, CD4 receptors were required both for effective fusion and for endocytosis of HIV virions. The addition of neutralizing anti-CD4 antibodies impaired both the fusion and endocytosis of X4 and R5 HIV-1 virions. Further, the endocytosis of X4 HIV-1 virions in the presence of AMD3100 was almost entirely limited to a CD4-positive subset of cells. In contrast, the chemokine coreceptors were not required for virion endocytosis, since efficient endocytosis of R5 virions occurred in SupT1 cells lacking CCR5.
Endocytosis of HIV virions is upregulated when the HIV fusion pathway is inhibited. HIV-1 fusion and endocytosis in human CEM (22) and Jurkat (30) T cells are balanced, with 40% of virions entering by fusion and 60% entering by endocytosis. However, when the fusion pathway was interrupted in SupT1 T cells or primary human T lymphoblasts by addition of the CXCR4 entry inhibitor AMD3100 (31), viral replication was inhibited, yet the overall entry of GFP-Vpr-labeled virions did not decline. In contrast, blocking anti-CD4 antibodies markedly diminished overall viral entry. These results suggest that inhibition of fusion is associated with a compensatory increase in endocytosis. Virion endocytosis in T cells is generally a "dead end" pathway leading to virion inactivation and degradation. However, as noted for other cell types, such as macrophages or dendritic cells, enhanced internalization of HIV virions by macropinocytosis (23) or DC-SIGN-mediated endocytosis (6, 15) , respectively, plays a key role in the infection of these or neighboring cells. In macrophages, macropinocytosis of HIV virions contributes to productive infection of these cells (23) . In dendritic cells, the binding of HIV virions to DC-SIGN followed by endocytosis of these virions into an acidified vesicular compartment and subsequent recycling of these vesicles to the cell surface appears to facilitate infection of interacting T cells (21) . Thus, entry of HIV virions into either the macropinocytic or endocytic compartment does not uniformly lead to virion inactivation and degradation. In most cells, however, including CD4 T cells, virion endocytosis does not contribute in a major manner to productive infection.
HIV-1 binding and entry via the fusion pathway are enhanced when endosome function is inhibited. We also explored whether enhanced entry of HIV virions by fusion occurs when the endocytotic pathway is inhibited. For these studies, cells were treated with two classes of endosome inhibitors, including bafilomycin A1 and concanamycin A, which block the vacuolar proton ATPase, and NH 4 Cl, a lysosomotropic weak base that neutralizes the endosome. The vacuolar proton ATPase inhibitors not only impair endosome acidification but, in some cell types, also impair trafficking from early to late endosomes (2) . As such, results obtained with these inhibitors must be interpreted with both potential effects in mind. Our results indicate that treatment of human T cells with bafilomycin A1, concanamycin A, or NH 4 Cl leads to a twofold to fourfold increase in fusion of HIV virions with target cells (Fig.  7A ) and a concomitant increase in cytosolic delivery of viral cores (Fig. 7B) , culminating in higher levels of HIV replication in these cells. Consistent with these results, treatment of epithelial HeLa-CD4 cells with endosome inhibitors increased HIV infectivity 2-to 15-fold (16) . We found that endosome inhibitors were most effective with viruses displaying relatively low infectivity, such as NL4-3⌬Nef or SF2 viruses, which are likely impaired for entry via the fusion pathway (1) and, thus, are more susceptible to endocytosis-mediated entry than WT NL4-3 viruses under steady-state conditions (14, 30) . It would be of interest in future studies to study the effects of endocytosis inhibitors on viruses with reduced entry due to compromised CD4 or chemokine coreceptor binding. Based on our observations of the ⌬Nef and SF2 virions in this study, we would predict that such viruses would also display enhanced replication in response to inhibition of endosome acidification. The compensatory changes between these two entry pathways when one is blocked reveal that inhibition of endocytosis may disproportionately increase virion entry by fusion, leading to increased infectivity.
Bafilomycin A1, concanamycin A, and, to a lesser extent, NH 4 Cl all enhanced entry of virions into target cells via fusion, ultimately leading to enhanced cytosolic delivery of HIV-1 cores. This increase cannot be explained by increased surface expression of CD4 or CXCR4. The most straightforward explanation is that these agents promote HIV fusion within endosomes. An alternative explanation for these results is that HIV virions trapped in early endosomes in the presence of bafilomycin A1 are transported back to the plasma membrane in recycling vesicles lacking CD4 and CXCR4. As such, productive fusion might occur at the cell surface as well as within the neutralized early endosomes.
HIV-1 infectivity reflects a dynamic balance between virion fusion and endocytosis. The infectivity of an HIV-1 particle is linked to its ability to fuse to its target cells. This process is cooperative and depends on receptor density, conformation, and envelope-receptor affinities (12) . Our findings help refine the understanding of the mechanism of HIV-1 entry into T cells and PBMCs. Overall entry reflects the amount of HIV-1 X4 or R5 virions bound to CD4 molecules. After the initial step of binding to CD4, viral entry involves a competition between the pathways of fusion and endocytosis, controlled by secondary interactions with specific coreceptors that trigger fusion or with other cell surface proteins that induce endocytosis. Inhibiting fusion increases endocytosis, while inhibiting endosome acidification and trafficking increases fusion. Thus, perturbations of the host cell that affect the balance between fusion and endocytosis could markedly influence viral infectivity. These findings also highlight how cell-cell fusion assays (34) do not fully recapitulate the dynamics of HIV virion entry, since the competition between fusion and endocytosis is lost. In contrast, the virion-based cell fusion assay appears to more faithfully recapitulate the cell surface dynamic competition between fusion and endocytosis, revealing the effect of endocytosis inhibitors on virion fusion. Our findings also agree with the conclusions of Fredericksen and colleagues (16) concern-ing the potential detrimental effects on HIV infectivity of administration of clinically approved drugs, such as amatadine and chloroquine, which impair endosomal acidification. In particular, these drugs may potentiate the effects of viruses displaying diminished infectivity.
